StreetInsider.com News Articles

CEL-SCI Corp (CVM) reported Q1 EPS

Thu, 19 Feb 2026 00:19:18 -0500

CEL-SCI Corp (NYSE: CVM) reported Q1 EPS of ($0.68).

For earnings history and earnings-related data on CEL-SCI Corp (CVM) click here.

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

“CEL-SCI is focused on two major value-driving milestones in the near term—starting enrollment in our U.S. FDA confirmatory Registration trial of Multikine in head and neck cancer and advancing Multikine globally in markets including Saudi Arabia. We

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal First Quarter 2026 Results

Wed, 18 Feb 2026 09:00:00 -0500

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study

Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

Form 10-Q CEL SCI CORP For: Dec 31

Tue, 17 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260217/26014849.html

Form 10-Q CEL SCI CORP For: Dec 31

Tue, 17 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260217/26014849.html

Form 4 CEL SCI CORP For: Jan 22 Filed by: KERSTEN GEERT R

Mon, 26 Jan 2026 08:23:00 -0500

si-local-file:///var/storage/secattach/20260126/25890648.html

Form 4 CEL SCI CORP For: Jan 22 Filed by: KERSTEN GEERT R

Mon, 26 Jan 2026 08:23:00 -0500

si-local-file:///var/storage/secattach/20260126/25890648.html

Form 4 CEL SCI CORP For: Dec 31 Filed by: TALOR EYAL

Mon, 05 Jan 2026 09:30:00 -0500

si-local-file:///var/storage/secattach/20260105/25802535.html

Form 4 CEL SCI CORP For: Dec 31 Filed by: TALOR EYAL

Mon, 05 Jan 2026 09:30:00 -0500

si-local-file:///var/storage/secattach/20260105/25802535.html

Form 4 CEL SCI CORP For: Dec 31 Filed by: PRICHEP PATRICIA B

Mon, 05 Jan 2026 09:27:00 -0500

si-local-file:///var/storage/secattach/20260105/25802489.html

Form 4 CEL SCI CORP For: Dec 31 Filed by: PRICHEP PATRICIA B

Mon, 05 Jan 2026 09:27:00 -0500

si-local-file:///var/storage/secattach/20260105/25802489.html

Form 4 CEL SCI CORP For: Dec 31 Filed by: KERSTEN GEERT R

Mon, 05 Jan 2026 09:23:00 -0500

si-local-file:///var/storage/secattach/20260105/25802463.html

Form 4 CEL SCI CORP For: Dec 31 Filed by: KERSTEN GEERT R

Mon, 05 Jan 2026 09:23:00 -0500

si-local-file:///var/storage/secattach/20260105/25802463.html

CEL-SCI Reports Fiscal 2025 Results

Mon, 29 Dec 2025 09:00:00 -0500

Filed for Breakthrough Designation for Multikine in Saudi Arabia
A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026
Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

“During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the

CEL-SCI Reports Fiscal 2025 Results

Mon, 29 Dec 2025 09:00:00 -0500

Filed for Breakthrough Designation for Multikine in Saudi Arabia
A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026
Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

“During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the

CEL-SCI Reports Fiscal 2025 Results

Mon, 29 Dec 2025 09:00:00 -0500

Filed for Breakthrough Designation for Multikine in Saudi Arabia
A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026
Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

“During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the

CEL-SCI Reports Fiscal 2025 Results

Mon, 29 Dec 2025 09:00:00 -0500

Filed for Breakthrough Designation for Multikine in Saudi Arabia
A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026
Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

“During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the

CEL-SCI Reports Fiscal 2025 Results

Mon, 29 Dec 2025 09:00:00 -0500

Filed for Breakthrough Designation for Multikine in Saudi Arabia
A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026
Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

“During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the

CEL-SCI Reports Fiscal 2025 Results

Mon, 29 Dec 2025 09:00:00 -0500

Filed for Breakthrough Designation for Multikine in Saudi Arabia
A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026
Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

“During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the